Lecanemab: A Second in Class Therapy for the Management of Early Alzheimer’s Disease
The Food and Drug Administration granted traditional approval of lecanemab for the treatment of Alzheimer’s disease (AD). Lecanemab is a humanized anti-amyloid monoclonal antibody directed towards Aβ protofibrils. Lecanemab is the only drug that targets Aβ soluble protofils and has shown statistica...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
University of Minnesota Libraries Publishing
2024-03-01
|
| Col·lecció: | INNOVATIONS in Pharmacy |
| Matèries: | |
| Accés en línia: | https://pubs.lib.umn.edu/index.php/innovations/article/view/5787 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|